Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Inclusion Criteria: Age: 18-70 Risk groups: All risk groups histology: diagnosis or a recurrent or primary progressive aggressive b-cell non-hodgkin lymphoma, in particular * follicular lymphoma grade III * diffuse large b-cell lymphoma * burkitt lymphoma * mantle cell lymphoma, blastoid variant * aggressive marginal zone lymphoma Performance status: ECOG 0-2 Criteria for women of childbearing potential: Women of childbearing potential have to: * understand the teratogenic risk associated with the study therapy, especially lenalidomide * understand the need of reliable, uninterrupted birth control from 4 weeks prior to the start of the study drug, during the duration of the study treatment, and 4 weeks after completion of study treatment, and be able to reliably use birth control, except if the patient commits to absolute sexual abstinence, confirmed on a monthly basis The following are effective methods of contraception: * implant * levonorgestrel-releasing intrauterine system (IUS) * medroxyprogesterone acetate depot * tubal sterilisation * sexual intercourse with a vasectomised male partner only, vasectomy must be confirmed by two negative semen analyses * ovulation-inhibitory progesterone-only pills If not established on effective contraception, the female subject must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated. * Understand that even if she has amenorrhea, she must follo…